Immunomodulatory drugs including thalidomide, lenalidomide (LEN) and pomalidomide (POM), are effective for treating multiple myeloma (MM). POM has shown enhanced efficacy with dexamethasone (DEX). Pegylated liposomal doxorubicin (PLD) with bortezomib is US Food and Drug Administration-approved for treating MM. PLD with LEN or thalidomide has shown efficacy for MM patients. LEN with DEX, PLD and bortezomib achieves high response rates. We evaluated the combination of POM with DEX 40 mg and PLD 5 mg/m 2 with the latter two drugs administered on days 1, 4, 8 and 11 on a 28-day cycle for the treatment of relapsed/refractory MM patients. During Phase 1, the maximum tolerated dose of POM was 4 mg, and was used in Phase 2, which also required patients to be refractory to LEN. However, neutropenia ≥ grade 3 was observed in 10/17 (59%) patients, and the dose was lowered to 3 mg. Median PFS was 5Á4 months (range, 0Á3-29Á0 + months). Overall response rates for patients in Phase 2 were 39% and 31% among subjects receiving POM at 3 mg and 4 mg, respectively, and clinical benefit rates were 51% and 44%, respectively. POM, PLD and DEX is a treatment option for relapsed/refractory MM patients including those who are refractory to LEN.
Multiple myeloma (MM) is a clonal plasma cell disorder diagnosed using standard criteria including plasmacytomas on tissue biopsy, bone marrow plasmacytosis, presence of lytic bone lesions and amount of monoclonal immunoglobulin (Durie, 1986; Rajkumar et al, 2014) . In the United States, there were more than 30 000 new cases and over 12 000 deaths estimated in 2016 (Siegel et al, 2016b) . The most common therapies for treating MM include combination regimens consisting of steroids, an immunomodulatory agent [thalidomide (THAL), lenalidomide (LEN) or pomalidomide (POM)], and a proteasome inhibitor (PI) consisting of either bortezomib (BORT) or carfilzomib (CAR) but recently, two monoclonal antibodies, daratumumab and elotuzumab , along with an oral PI, ixazomib, have also been approved for the treatment of relapsed or refractory MM (RRMM). These drugs, depending on the patient profile, are combined with a low-dose dexamethasone (DEX) regimen to minimize toxicity and, often, other agents to improve their efficacy (Lacy et al, 2010; Mateos et al, 2016; Siegel et al, 2016a) .
Pomalidomide is an immunomodulatory drug that has shown greater anti-tumour activity in the laboratory than THAL and LEN (Chanan-Khan et al, 2013) . The most common toxicities from POM are myelosuppression leading to anaemia, thrombocytopenia and neutropenia. A Phase 1 open-label dose-escalation study evaluated 2, 3, 4,and 5 mg of POM administered daily (Schey et al, 2004) on days 1-28 of each 28-day cycle or on alternate days (Streetly et al, 2008) , and found that doses up to 5 mg were well tolerated with the 4 mg dose resulting in the best response rates. Another Phase 1 dose-escalation trial showed 4 mg daily to be the recommended and maximum tolerated dose (MTD) of POM when administered for 21 consecutive days of a 28-day cycle (Richardson et al, 2013a) . A number of Phase 2 trials were conducted using POM and DEX in varying RRMM patient populations to analyse response rates, survival and toxicity (Lacy et al, 2009 (Lacy et al, , 2010 (Lacy et al, , 2011 Richardson et al, 2014) . One of these studies, a Phase 2 trial of POM in combination with low-dose DEX showed an overall response rate (ORR) of 63% and a median progression-free survival (PFS) of 11Á6 months in high-risk patients (Lacy et al, 2009 ). Responses were also achieved among patients refractory to treatment with LEN, THAL and BORT. The addition of DEX to POM doubled the response rate and median PFS compared to POM alone . In this study, the median PFS was 4Á6 months for patients who had received prior therapies with LEN and BORT. To further analyse and compare the efficacy and safety of POM with low-dose or high-dose DEX among subjects with RRMM, a Phase 3 trial was conducted measuring PFS as a primary outcome measure (San Miguel et al, 2013 . The PFS for low-dose DEX and POM was 4 months versus 1Á9 months for the high-dose DEX arm (San Miguel et al, 2013) . Patients treated with the low-dose DEX and POM showed a higher ORR (31%) than those treated with the high-dose DEX (ORR = 10%) (San Miguel et al, 2013) . Additional preclinical work has demonstrated the synergistic activity of the combination of DEX and POM and showed that this combination displays synergistic anti-tumour responses consisting of anti-proliferative and pro apoptotic responses (Rychak et al, 2016) . Furthermore, in LEN resistant human MM models, gene expression profiling displayed unique changes in pro-apoptotic and immunomodulatory pathways, indicating a specific potential molecular mechanism for this phenomenon (Rychak et al, 2016) . Despite the clinical activity of the combination of POM and DEX for RRMM patients, the outcome of patients treated with POM and DEX was still poor; and, therefore, POM and DEX have been combined with other drugs in triplets to increase efficacy of therapies for RRMM (Bringhen et al, 2016; Hobbs et al, 2016) .
Trials have also been conducted combining immunomodulatory drugs, THAL or LEN, with pegylated liposomal doxorubicin (PLD) because they have unique but complementary mechanisms and non-overlapping toxicities showing significant clinical benefit Hussein et al, 2006; Offidani et al, 2006a,b; Berenson et al, 2011 Berenson et al, , 2012 Jakubowiak et al, 2011) . Additionally, a preclinical in vivo study by Campbell et al (2006) demonstrated that low doses of PLD administered once daily on three consecutive days on a weekly basis to severe combined immune deficient mice greatly decreased MM xenograft growth and human paraprotein plasma levels, whereas the same total dose given once weekly had no anti-myeloma effects. As a result, we evaluated low dose PLD (5 mg/m 2 ) in combination with reduced BORT (1Á0 mg/m 2 ) with intravenous (IV) DEX 40 mg all administered on days 1, 4, 8 and 11 of a longer 28-day cycle for previously untreated MM patients (Berenson et al, 2011) and this same combination with PLD at 4 mg/m 2 and LEN for those with RRMM (Berenson et al, 2012) . For the latter study, 85% of the evaluable patients achieved clinical responses. Later, the combination of the PI CAR, the immunomodulatory agent POM, and DEX were evaluated for MM patients refractory to LEN, and demonstrated that it was a well-tolerated regimen with high response rates [ORR 50% and clinical benefit rate (CBR) 66%] (Shah et al, 2015) . A recently reported case study also showed promising results for POM with low-dose DEX for a patient with secondary plasma cell leukaemia (Mele et al, 2016) , which generally has a very poor prognosis with an expected median survival of 1-2 months (Cha et al, 2007) . The patient was still alive and continuing to respond with a significant reduction of circulating plasma cells 6 months after diagnosis (Mele et al, 2016) . Although POM has shown significant anti-myeloma efficacy for treating RRMM patients, MM patients treated with this drug recur with their disease even after initially responding (Orlowski, 2013) . Thus, there is a constant need to develop new therapies, especially combinations with other active agents to treat MM in order to improve the outcome for these patients.
Thus, we have now completed the first clinical trial evaluating PLD with POM and DEX for MM patients. Specifically, we conducted a Phase 1/2 trial evaluating this combination with DEX for previously treated MM patients in order to determine the efficacy, safety and tolerability of this regimen. For Phase 1, POM was given at daily dosages of 2 (Cohort 1), 3 (Cohort 2), or 4 (Cohort 3) mg per os (PO) daily (for days 1-22) in combination with IV DEX at 40 mg and PLD at 5 mg/m 2 on days 1, 4, 8 and 11 of each 28-day cycle. Notably, the patients enrolled in the Phase 2 portion of the trial were required to be refractory to LEN, and received POM dosing at 3 mg after enhanced toxicity was observed during the initial enrolment at 4 mg, which was established as the MTD in the Phase 1 portion of the trial. Overall, combining 3 mg POM with PLD and DEX using a modified 28-day cycle schedule proved to be safe and effective for MM patients who were refractory to previous LEN-containing regimens.
Materials and methods

Patient population
The inclusion criteria were that patients had to be over 18 years of age with a diagnosis of MM based on standard criteria (Durie, 1986; Rajkumar et al, 2014) Subjects had to also meet the following laboratory test criteria: absolute neutrophil count ≥1Á5 9 10 9 /l, platelet count ≥ 75 910 9 /l, haemoglobin ≥80 g/l, calculated or measured creatinine clearance of at least 30 ml/min, total bilirubin ≤1Á5 9 upper limit of normal (ULN), aspartate transaminase and alanine transaminase ≤2 9 ULN or ≤5 9 ULN if hepatic metastases are present, and serum potassium within the normal range. The exclusion criteria were any subjects with plasma cell dyscrasia with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) syndrome, plasma cell leukaemia or primary amyloidosis. Subjects with non-haematological malignancy within the past 5 years or impaired cardiac function were also not eligible. The protocol was designed in accordance with the general ethical principles of the Declaration of Helsinki. 
Study design
This study was a multi-centre, open-label, non-randomized study consisting of a POM dose-finding Phase 1 portion for RRMM patients followed by a Phase 2 portion for only LENrefractory MM patients. The study consisted of a screening period, followed by up to eight 28-day treatment cycles, a final assessment occurring 28 days after the end of the last treatment and a follow-up period.
There were 3 cohorts included in the Phase 1 portion who received POM at 2 mg (Cohort 1), 3 mg (Cohort 2) or 4 mg (Cohort 3) administered once daily starting on day 1 for 21 consecutive days of a 28-day cycle. Patients also received DEX at 40 mg and PLD at 5 mg/m² both given IV on days 1, 4, 8, and 11 of a 28-day cycle based on previous studies from our group (Berenson et al, 2011) . Patients in the Phase 2 portion must have also been refractory to their last LENcontaining regimen. Initially, a dose of 4 mg of POM was used for the Phase 2 portion of the trial based on the results of the Phase 1 study. However, because of the frequent occurrence of neutropenia, the trial was amended so that the remainder of patients enrolled in the Phase 2 portion of the trial received 3 mg of POM (Table I) .
During screening, patients underwent the following assessments: demographics, medical history, inclusion/exclusion criteria, concomitant medications, ECOG performance status, physical examination, vital signs, height and weight, 12-lead electrocardiogram, echocardiogram or multigated acquisition (MUGA) scan, chest radiograph, roentgenographic survey of bones, bone marrow aspirate and biopsy, serum b-2 microglobulin, MM disease parameter assessments, clinical laboratory evaluation including haematology, serum chemistry, amylase, urinalysis and a pregnancy test for females of child-bearing potential.
During the study treatment period, Day 1 assessments of each 28-day cycle consisted of inclusion/exclusion criteria, vital signs, height and weight, body surface area, interval history and symptom-directed physical examination, ECOG performance status, haematology [complete blood counts (CBC)], serum chemistry, serum pregnancy testing and counselling, and response assessment. Day 4 assessments included vital signs and CBC and serum chemistry laboratory tests. Day 8 assessments were identical to Day 4 with the inclusion of serum pregnancy testing and counselling. Day 11 assessments were vital signs, interval history and symptom-directed physical examination, ECOG performance status, CBC and serum chemistry laboratory tests.
For end of study treatment visit, 28 days after last dose of study drug, the following assessments were completed: vital signs, height and weight, complete physical examination, ECOG performance status, CBC, serum chemistry, amylase, serum pregnancy testing and counselling, serum b-2 microglobulin, MM assessments and an overall response assessment. 
Endpoints
The primary endpoint for the Phase 1 portion of the trial was to establish the MTD of POM in combination with DEX and PLD for patients with RRMM. The primary objectives for the Phase 2 part of the study were to determine the efficacy of this combination among MM patients refractory to LEN based on the ORR, which was defined as the proportion of patients achieving either complete response (CR) + very good partial response (VGPR) + partial response (PR), and CBR, which was defined as the proportion of patients achieving CR, VGPR, PR and minor response (MR). Secondary objectives for the Phase 1 and 2 parts of the study were to establish the safety, tolerability, PFS, time to first response and duration of response (DOR) for RRMM patients receiving the combination of POM, DEX and PLD.
Statistical analysis
PFS was defined as the duration from the initiation of therapy to disease progression or death from any cause, whichever occurred first. Disease progression was defined based on the International Myeloma Working Group (IMWG) criteria for MM (Durie, 1986; Rajkumar et al, 2014) . DOR was defined as the time from the first response to progressive disease (PD). PFS and DOR were analysed using the KaplanMeier method. Subjects who did not progress or withdrew from the study were treated as censored data. The analysis was done using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA).
Results
Enrolment, dosing and patient demographics
Seventy patients were enrolled in this study; however, 2 patients did not meet the requirements for this trial; and, therefore, only 68 patients who received study drug were both evaluable for efficacy and safety (11 patients in Phase 1, 57 patients in Phase 2). The median age of the subjects was 66 years old and the patient population consisted of 41 males and 29 females. In terms of prior regimens, the median number of overall previous treatments was 4 (range, 1-18). Specifically, a median of 0 (range, 0-3) were PLD-containing regimens, 1 (range, 0-8) was an immunomodulatory drug-containing regimen, 0 (range, 0-3) were LEN and BORT-containing regimens, 0 (range, 0-1) were both immunomodulatory drug and PLD-containing regimens and 0 (range, 0-2) were patients with prior stem cell transplant regimens (Table I ). The median number of cycles completed for all patients treated in the Phase 1 and 2 portions of the trial was 3 (range, 1-8 cycles; Table II ). The same median number of cycles completed was also observed for patients enrolled in the Phase 2 part of the study. The median follow-up was 6Á7 months among all patients treated on the trial, which was identical to the median follow-up time for patients enrolled in the Phase 2 portion. During the study, there were 4 patients (Phase 2) with dose limiting toxicities that resulted in reductions in the dose of POM (Table I) . During the Phase 1 portion, 3, 4 and 4 patients received 2, 3 and 4 mg of POM, respectively (Table III) . Phase 2 was initially continued with administration of the 4 mg dose of POM and 16 patients were enrolled in the study before the protocol was amended. The dose of POM was reduced to 3 mg because of the high frequency of neutropenia [Grade 1 (25Á5%), 2 (23Á4%), 3 (38Á3%) and 4 (12Á8%)], among patients treated with the 4 mg POM dose. Of these patients, 3 had ≥ Grade 2 neutropenia accompanied by neutropenic fever. Ph1, phase 1; Ph2, phase 2; POM, pomalidomide. The maximum tolerated dose was initially declared at 4 mg; however, because of observed toxicity at that dose among patients enrolled into the Phase 2 portion of the study, the protocol was amended to lower the POM dose to 3 mg for all subsequently enrolled patients. Initially for the Phase 2 portion, the patients were dosed at the maximum tolerated dose of POM (4 mg) determined from the Phase 1 portion. Due to the frequent occurrence of severe neutropenia (≥Grade 3) observed among patients receiving 4 mg of POM during the Phase 2 portion, the dose was reduced to 3 mg.
After this modification, 40 patients then received POM at the 3 mg dose in the Phase 2 part of the study. All of these patients also received 40 mg of IV DEX and 5 mg/m² of PLD according to the planned protocol-defined schedule.
Efficacy endpoints were compared between patients receiving 4 mg of POM and those receiving 3 mg of POM (Tables IV and V) . Patients receiving 4 mg of POM in this combination showed ORR of 30% for Phase 1 and 2 combined, and 31% for Phase 2 alone, which required patients to be refractory to LEN. The CBR was 40% for patients enrolled in the Phase 1 and 2 parts, and 44% for those that were part of the Phase 2 portion. For the group of patients receiving 3 mg of POM (Table V) , 4 patients (10%) from the Phase 2 portion showed a complete response (CR). The ORR for patients who received 3 mg of POM as part of the Phase 1 and Phase 2 (combined) or Phase 2 were 42% and 39%, respectively, and the CBRs were 53% (Phase 1 and 2 combined) and 51% (Phase 2 alone).
Of 68 evaluable patients, 26 (38%) patients had prior LEN and BORT-containing regimens (Table I ) with 9 and 17 patients receiving 4 mg or 3 mg of POM, respectively. Efficacy endpoints showed slightly worse outcomes for patients with prior LEN-and BORT-containing regimens as compared to the overall patient population. Patients receiving 4 mg of POM showed an ORR of 22% and CBR of 33%, and those receiving 3 mg of POM had an ORR of 23% and CBR of 47% (data not shown).
Progression-free survival and duration of response PFS was calculated for all patients in the Phase 2 arm of the study. Patients receiving 4 mg of POM were also compared to those receiving 3 mg. For all patients enrolled in the Phase 2 portion, the median PFS was 5Á4 months (Fig 1A) . From those patients, those receiving 4 mg of POM showed a PFS also of 5Á4 months (Fig 1B) compared to 4Á8 months for patients receiving 3 mg (Fig 1C) .
The same analysis was performed to determine the DOR. For the total patient population within the Phase 2 portion of the study, the median DOR was 4Á8 months (Fig 2A) . When comparing those receiving 4 mg compared with 3 mg, the median DOR times were similar (4Á8 and 4Á9 months, respectively) (Fig 2B and C) .
Safety
Adverse events (AEs) are listed in Table VI while serious adverse events (SAEs) are shown in Table VII . The total number of patients who experienced a particular AE is shown in the table based on grade. The most common haematological AEs (all grades; any cause) were neutropenia (69%), leucopenia (54%), lymphopenia (51%), hypokaleamia (38%), thrombocytopenia (34%), high blood urea nitrogen (32%) and hyperglyceamia (29%). For the 47 patients suffering from the most common AE, neutropenia, 12 (25%), 11 (23%), 18 (38%) and 6 patients (13%) had Grade 1, 2, 3 8 (40) 7 (44) CBR, clinical benefit rate; ORR, overall response rate; POM, pomalidomide. 24 (53) 21 (51) CBR, clinical benefit rate; ORR, overall response rate; POM, pomalidomide. and 4 neutropenia, respectively, although none were classified as SAEs. There were 8 patients experiencing ≥Grade 4 AEs: hypoglycaemia (n = 1), lymphopenia (n = 1) and neutropenia (n = 6). For non-haematological AEs, the most common were hyponatraemia (41%) and fatigue (32%), while constipation, fever and upper respiratory infection also frequently occurred (16% each). Of those suffering from hyponatraemia, 75% were Grade 1 and 25% were Grade 3 AEs. Eight patients experienced non-haematological SAEs that were study drugrelated and 10 patients experienced SAEs that were not drugrelated after receiving study drug (Table VII) .
Discussion
Despite recent improvements in overall survival (OS), MM remains an incurable disease with a median OS of 7 years . The advent of new and more effective drugs, both alone and in combination, has quickly and dramatically increased the number of therapeutic options available to patients, particularly in the relapsed/refractory setting. Preclinical studies have shown that the replacement of the first and second-generation drugs with later generation agents from the same class can overcome drug resistance. For example, MM tumour-bearing mice progressing from LEN, a second-generation immunomodulatory agent, plus DEX treatment were switched to POM, a third-generation immunomodulatory agent, plus DEX and showed a significant reduction in tumour volume (Ocio et al, 2015) .
These findings were supported by several phase I and II clinical trials that evaluated the efficacy and safety of POM monotherapy in MM patients with multiple prior therapies and showed improvement in ORR (Lacy et al, 2009; Richardson et al, 2013b) . Furthermore, San Miguel et al (2015) established that POM combined with low-dose DEX for treating BORT and LEN refractory patients showed significantly improved PFS and OS as compared to those receiving high-dose DEX alone. Monotherapy with POM showed a modest improvement in the outcomes for RRMM patients. Therefore, exploration of POM plus DEX in combination with other drugs has become an increasingly studied approach in the RRMM setting (Lacy et al, 2009; Richardson et al, 2013b) .
POM and low-dose DEX had been combined with several new PIs. For example, combining weekly CAR with POM and low-dose DEX did not show consistent improvement in patient outcomes. A Phase I/II trial (Bringhen et al, 2016) showed increased PFS among patients treated with CAR plus POM/low-DEX as compared with patients receiving the combination without the PI, whereas a retrospective study examining a similar patient population did not show an improvement in PFS (Hobbs et al, 2016) . A higher ORR was observed when POM/low-dose DEX was combined with the oral PI, ixazomib. However, it appeared to only benefit MM patients with high-risk cytogenetics, but the number of patients was small (Krishnan et al, 2016) .
POM/low-dose DEX has also been tested in combination with humanized antibodies, such as the CD38-targeted antibodies daratumumab and isatuximab and the checkpoint inhibitor pembrolizumab. Daratumumab with POM/lowdose DEX showed an ORR of 41% with 5% of patients achieving a CR (Branca et al, 2016 ).
Lastly, a high level of synergy exists between treatment with POM/low-dose DEX and citarinostat (ACY-241), a selective histone deacetylase 6 inhibitor (North et al, 2017) . A Phase 1a/1b trial showed that 56 efficacy-evaluable RRMM patients receiving this combination therapy had an ORR of 46% and a median PFS of 6Á5 months (Niesvizky et al, 2016) .
Despite the recent increase in the number of novel POMcontaining combination regimens evaluated for RRMM patients, anthracyclines, such as PLD, given in combination with POM have not yet been assessed in this clinical setting. (23) 14 (40) 12 (34) 1 (3) 35 (51) Monocytes (high) 16 (100) 0 (0) 0 (0) 0 (0) 16 (23) Neutropenia 12 (25) 11 (23) 18 (38) 6 (13) 47 ( 
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Previous studies from our group have shown that combining a PI, specifically BORT at 1Á0 mg/m 2 , with PLD and DEX (DVD) using a longer 4-week treatment cycle showed reduced toxicity, especially peripheral neuropathy, and durable efficacy for previously untreated MM patients (Berenson et al, 2011) . When this combination was subsequently used with the immunomodulatory agent LEN (DVDR) for treating RRMM patients, 85% of the subjects showed clinical responses (Berenson et al, 2012) . In addition to overcoming drug resistance, the obvious goal of developing novel therapies is also to achieve better ORRs, longer PFS and an improved safety profile. In the treatment of myeloma, PLD has demonstrated equivalent efficacy and better pharmacokinetic and tolerability profiles compared with that of conventional doxorubicin. In a randomized phase 3 study, the combination of PLD with the PI, BORT, was superior to BORT monotherapy for the treatment of patients with RRMM (Orlowski et al, 2007) . The combination of BORT with PLD, significantly prolonged time to progression compared to BORT alone (9Á3 months and 6Á5 months, respectively), although no significant improvement of long-term survival was obtained (Orlowski et al, 2007; Orlowski, 2013) . Despite this improvement in time to progression, PLD plus BORT was also associated with higher incidence of grade 3 or 4 adverse events than BORT alone.
Taken together, these findings led us to evaluate the novel combination regimen containing POM/low-DEX and an anthracycline, PLD, for treating RRMM patients. First, a Phase 1 portion of the trial was completed to determine the dose of POM that could be safely administered daily on days 1-21 of a 28-day cycle with our modified IV DEX and PLD doses and schedule, as we had previously established (Berenson et al, 2011) . This combination treatment appeared to be well-tolerated at the highest dose of the immunomodulatory agent tested, 4 mg, with no dose-limiting toxicities during the Phase I portion of the trial. However, in the Phase II portion of the trial, significantly high rates of haematological toxicity [≥ Grade 3 neutropenia in 10 (59%) out of the 17 total patients who were enrolled at the time] resulted in amending the study protocol reducing the dose of POM from 4 mg to 3 mg for the remainder of patients enrolled on the trial.
The occurrence of neutropenia in MM patients was consistent with reports from a recent trial that dose reductions and interruptions of POM due to AEs occurred in 22Á0% and 66Á3% of patients receiving the 4 mg dose of POM with DEX, respectively (Dimopoulos et al, 2016) . Neutropenia was also one of the most frequent AEs leading to dose reduction in patients receiving POM with DEX without anthracyclines (San Miguel et al, 2013) .
Efficacy data for patients taking 4 mg of POM from the Phase 1 and 2 parts of the trial combined showed an ORR of 30% and a CBR of 40%; response data for the Phase 2 portion, in which patients had to be LEN-refractory to be enrolled, showed a similar ORR of 31% and CBR of 44%. While there was no difference in the ORR compared to results from a study evaluating POM+DEX alone (ORR 32%) (Lacy et al, 2009) , data on CBR was not reported in that study and the observed PFS of 5Á4 months for patients receiving 4 mg of POM with PLD+DEX was longer as compared to that reported in the MM-010 (Dimopoulos et al, 2016) or MM-003 (San Miguel et al, 2013) studies, 4Á6 and 4Á0 months, respectively. Similarly to our study, both of the above mentioned trials enrolled LEN-refractory patients. Although the 4 mg dose of POM, when combined with DEX, showed significant clinical efficacy, it also caused increased toxicity, especially neutropenia. An improvement in both clinical benefits (ORR and PFS) and safety was observed for patients taking 3 mg of POM with PLD+DEX as part of either the Phase 1 and 2 (combined) or Phase 2 portion of the trial. The ORR was 42% (Phase 1 and 2) which was similar to that observed for LENrefractory patients (Phase 2; ORR = 39%) and both were slightly higher as compared to ORR of 33% (Dimopoulos et al, 2016) and 34% (San Miguel et al, 2013) in POM+DEX treated patients.
For the Phase 2 part of the trial, among patients receiving 3 mg of POM, 4 (10%) achieved CR and 10 (24%) achieved PR. These patients experienced less toxicity than those receiving POM at 4 mg. No patient receiving 4 mg POM achieved a CR; however, 5 (31%) patients achieved a PR and 2 (13%) achieved MR. The PFS for the LEN-refractory population treated with 3 mg of POM in the Phase 2 portion of this study was 4Á8 months, which was similar to the PFS in the studies evaluating POM with low-dose DEX which also included LEN-refractory patients, 4Á6 (Dimopoulos et al, 2016) and 4Á2 months (San Miguel et al, 2013) .
Overall, our results demonstrate the efficacy and durability of responses to POM in combination with PLD and DEX for treating MM patients who are refractory to LEN. We show that this novel combination, consisting of POM at 3 mg with our modified schedule using a 28-day cycle of IV PLD and DEX, is well tolerated and results in clinically important efficacy. This is the first study evaluating the combination of anthracyclines with the most recently approved immunomodulatory agent, POM, for treating MM patients.
